Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Dr. Patel on Emerging Therapeutic Strategies in MCL

March 20th 2019

Krish Patel, MD, medical oncologist, Swedish Cancer Institute, discusses emerging therapeutic strategies and ongoing research in mantle cell lymphoma (MCL).

Despite Progress in Follicular Lymphoma and MCL, Critical Questions Remain

March 20th 2019

Izidore S. Lossos, MD, discusses the current pillars of care and barriers in the treatment of patients with early-stage and advanced follicular lymphoma, as well as mantle cell lymphoma.

Dr. Lossos on Treatment Approaches in MCL

March 19th 2019

Izidore S. Lossos, MD, professor, director, Lymphoma Program Head of hematological malignancies site disease group, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses treatment approaches for patients with mantle cell lymphoma (MCL).

Stratification Schemes Guide Treatment Decisions in MCL

March 19th 2019

Andre Goy, MD, MS, shares insight on the stratification of patients with mantle cell lymphoma and other molecular markers that are being applied towards optimal treatment decisions in this disease.

Dr. Goy on Molecular Features of Mantle Cell Lymphoma

March 15th 2019

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the molecular features of mantle cell lymphoma (MCL).

Dr. Patel Discusses Zanubrutinib in MCL

March 11th 2019

Krish Patel, MD, medical oncologist, Swedish Cancer Institute, discusses zanubrutinib in the treatment of patients with mantle cell lymphoma.

Dr. Goy Discusses Challenges in Treatment of MCL

March 6th 2019

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses challenges in the treatment of patients with mantle cell lymphoma.

Using BTK Inhibitors in Community Practice

March 4th 2019

BTK Combination Strategies for B-Cell Malignancies

March 4th 2019

BTK Inhibitors in Chronic Lymphocytic Leukemia

March 4th 2019

New and Emerging BTK Inhibitors in Mantle Cell Lymphoma

March 4th 2019

First-Generation BTK Inhibition in Mantle Cell Lymphoma

March 4th 2019

BTK Inhibitors in Waldenstrom Macroglobulinemia

March 4th 2019

Resistance to BTK Inhibitors in B-Cell Malignancies

March 4th 2019

BTK Inhibitors Explored in B-Cell Malignancies

March 4th 2019

Targeting BTK in B-Cell Malignancies

March 4th 2019

Genomic Profiling in Chronic Lymphocytic Leukemia

March 4th 2019

Diagnosing Waldenstrom Macroglobulinemia

March 4th 2019

Watch-and-Wait Approach Can Be Beneficial Strategy in MCL

March 3rd 2019

Prognostic indices for mantle cell lymphoma are good for classifying patients but do little in the way of guiding treatment, and often the best course of action is to watch and wait.

Dr. Wang Discusses Promise of Venetoclax in MCL

March 2nd 2019

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the promise of venetoclax in the treatment of patients with relapsed/refractory mantle cell lymphoma.

x